Schizophrenia-Psychotic Disorders & Antipsychotics

 (Haga un click en la información del journal para acceder al resúmen)

5 – doble-ciego o metanálisis; 4 – subanálisis o simple ciego; 3 – revisión, abierto, básico; 2 – casos; 1 – opinión

 

3 - Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia

Xiang Yang Zhang, Da Chun Chen, Ling Yan Qi, Fang Wang, Mei Hong Xiu, Song Chen, Gui Ying Wu, Therese A. Kosten and Thomas R. Kosten

Psychopharmacology. Volume 205, Number 4 / September, 2009: 647-654

 

3 - Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia

Kyoung-Uk Lee, Yang-Whan Jeon, Hae-Kook Lee, Tae-Youn Jun

Human Psychopharmacology: Clinical and Experimental. Volume 24 Issue 6, Pages 447 - 452

 

3 - Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT_1A receptor agonist

Danijela Piskulic, James S. Olver, Paul Maruff, Trevor R. Norman

Human Psychopharmacology: Clinical and Experimental. Volume 24 Issue 6, Pages 437 - 446

 

3! - Predictors of 10-year outcome of first-episode psychosis

C. White, J. Stirling, R. Hopkins, J. Morris, L. Montague, D. Tantam and S. Lewis

Psychological Medicine (2009), 39:1447-1456

 

3! - Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: A meta-analysis

Stéphane Potvin, Pierre Blanchet and Emmanuel Stip

Schizophrenia Research. Volume 113, Issues 2-3, September 2009, Pages 181-188

 

GRATIS (previo registro) 3 - Predisposición al consumo de alcohol y drogas en personas vulnerables a la esquizofrenia

A. Fumero, C. Santamaría, G. Navarrete

REV NEUROL 2009;49:8-12

 

3! - Evidence that better outcome of psychosis in women is reversed with increasing age of onset: A population-based 5-year follow-up study

Sebastian Köhler, Margriet van der Werf, Brian Hart, Gary Morrison, Robin McCreadie, Brian Kirkpatrick, Mike Verkaaik, Lydia Krabbendam, Frans Verhey, Jim van Os and Judith Allardyce

Schizophrenia Research. Volume 113, Issues 2-3, September 2009, Pages 226-232

 

3! - Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia

Monika Edlinger, Alex Hofer, Maria A. Rettenbacher, Susanne Baumgartner, Christian G. Widschwendter, G. Kemmler, Nazanin Ahmadian Neco and W. Wolfgang Fleischhacker

Schizophrenia Research. Volume 113, Issues 2-3, September 2009, Pages 246-251

 

3 - Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study

Alptekin, Koksal; Hafez, Jamal; Brook, Shlomo; Akkaya, Cengiz; Tzebelikos, Errikos; Ucok, Alp; Tallawy, Hamdy El; Danaci, Aysen-Esen; Lowe, Wing; Karayal, Onur N

International Clinical Psychopharmacology: September 2009 - Volume 24 - Issue 5 - pp 229-238

 

3 - Impact of antipsychotic treatments on the motivation to eat: preliminary results in 153 schizophrenic patients

Sentissi, Othman; Viala, Annie; Bourdel, Marie C.; Kaminski, Flaminia; Bellisle, France; Olié, Jean P.; Poirier, Marie F.

International Clinical Psychopharmacology: September 2009 - Volume 24 - Issue 5 - pp 257-264

 

3! - Depot and oral antipsychotics: patient preferences and attitudes are not the same thing

MX Patel, N De Zoysa, M Bernadt, A David

Journal of Psychopharmacology, Vol. 23, No. 7, 789-796 (2009)

3 - Long-term treatment with flupentixol results of a post-marketing surveillance study

T Messer, T Glaser, H Landen, M Schmauss

Journal of Psychopharmacology, Vol. 23, No. 7, 805-813 (2009)

5< - Modafinil for Clozapine-Treated Schizophrenia Patients: A Double-Blind, Placebo-Controlled Pilot Trial

Oliver Freudenreich, David C. Henderson, Eric A. Macklin, A. Eden Evins, Xiaoduo Fan, Cori Cather, Jared P. Walsh, and Donald C. Goff

J Clin Psychiatry. Online ahead of print: August 11, 2009

 

3! - Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol

Antonio R. Sa, Ana G. Hounie, Aline S. Sampaio, Jony Arrais, Euripedes C. Miguel and Helio Elkis

Comprehensive Psychiatry. Volume 50, Issue 5, September-October 2009, Pages 437-442

 

3 - Treatment response in psychotic patients classified according to social and clinical needs, drug side effects, and previous treatment; a method to identify functional remission

Malin Alenius, Margareta Hammarlund-Udenaes, Per Hartvig, Staffan Sundquist and Leif Lindström

Comprehensive Psychiatry. Volume 50, Issue 5, September-October 2009, Pages 453-462

 

3 - Evidence for the Partial Dopamine-Receptor Agonist Aripiprazole as a First-Line Treatment of Psychosis in Patients With Iatrogenic or Tumorogenic Hyperprolactinemia

Zachary S. Hoffer, Richard L. Roth, and Maju Mathews

Psychosomatics 50:317-324, July-August 2009

3 - The incidence of diabetes in atypical antipsychotic users differs according to agent - results from a multisite epidemiologic study

Marianne Ulcickas Yood, Gerald deLorenze, Charles P. Quesenberry Jr, Susan A. Oliveria, Ai-Lin Tsai, Vincent J. Willey, Robert McQuade, John Newcomer, Gilbert L'Italien

Pharmacoepidemiology and Drug Safety. Volume 18 Issue 9, Pages 791 - 799

 

3 - Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved

Arne Mørk, Louise M. Witten and Jørn Arnt

Psychopharmacology. Volume 206, Number 1 / September, 2009: 39-49

 

3 - Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia

Henrik Walter, Hannes Kammerer, Karel Frasch, Manfred Spitzer and Birgit Abler

Psychopharmacology. Volume 206, Number 1 / September, 2009: 121-132

 

3 - Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats

Montserrat Victoriano, Dominique Hermier, Patrick C. Even, Gilles Fromentin, Jean-François Huneau, Daniel Tomé and Renaud de Beaurepaire

Psychopharmacology. Volume 206, Number 1 / September, 2009: 167-176

 

3! - Validity of the Prodromal Risk Syndrome for First Psychosis: Findings From the North American Prodrome Longitudinal Study

Scott W. Woods, Jean Addington, Kristin S. Cadenhead, Tyrone D. Cannon, Barbara A. Cornblatt, Robert Heinssen, Diana O. Perkins, Larry J. Seidman, Ming T. Tsuang, Elaine F. Walker and Thomas H. McGlashan

Schizophrenia Bulletin 2009 35(5):894-908

 

3! - Secondary Effects of Antipsychotics: Women at Greater Risk Than Men

Mary V. Seeman

Schizophrenia Bulletin 2009 35(5):937-948

 

3 - Is Early Intervention in Psychosis Cost-Effective Over the Long Term?

Cathrine Mihalopoulos, Meredith Harris, Lisa Henry, Susy Harrigan and Patrick McGorry

Schizophrenia Bulletin 2009 35(5):909-918

 

3 - Aripiprazole: Dose-Response Relationship in Schizophrenia and Schizoaffective Disorder

Mace, Shubhra; Taylor, David

CNS Drugs: 1 September 2009 - Volume 23 - Issue 9 - pp 773-780

 

3 - Asenapine

Weber, Juliane; McCormack, Paul L

CNS Drugs: 1 September 2009 - Volume 23 - Issue 9 - pp 781-792

 

3! - Effectiveness and tolerability of long-acting risperidone: A 9-month open-label extension of a 12-week switching study from oral antipsychotics

Chang Yoon Kim;  Seockhoon Chung;  Bong-Jin Hahm;  Kyung Sue Hong;  Jin-Sang Yoon;  Young-Hoon Kim;  Won-Myong Bahk;  Sang-Yeol Lee;  Yanghyun Lee;  In-Won Chung; Chan-Hyung Kim

International Journal of Psychiatry in Clinical Practice, Volume 13, Issue 3 September 2009, pages 192 - 198

 

3 - The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year

S.G. Schorr, C.J. Slooff, R. Bruggeman and K. Taxis

Journal of Psychiatric Research. Volume 43, Issue 13, September 2009, Pages 1106-1111

 

3! - Pharmacokinetic and Pharmacodynamic Interactions Between Carbamazepine and Aripiprazole in Patients With Schizophrenia

Nakamura, Akifumi; Mihara, Kazuo; Nagai, Goyo; Suzuki, Takeshi; Kondo, Tsuyoshi

Therapeutic Drug Monitoring: 20 August 2009

 

5 - Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: A mixed treatment comparison of randomized controlled trials

Steven J. Edwards and Christopher J. Smith

Clinical Therapeutics. Volume 31, Part 1, 2009, Pages 1345-1359

3! - Sertindole causes distinct electrocardiographic T-wave morphology changes

Jimmi Nielsen, Claus Graff, Thomas Hardahl, Mads P. Andersen, Jens Kristoffersen, Johannes J. Struijk, Egon Toft and Jonathan M. Meyer

European Neuropsychopharmacology. Volume 19, Issue 10, October 2009, Pages 702-707

 

3 - Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex

Satoshi Yamamura, Keiko Ohoyama, Tatsuya Hamaguchi, Kanae Kashimoto, Masanori Nakagawa, Shinichi Kanehara, Dai Suzuki, Takuya Matsumoto, Eishi Motomura, Takashi Shiroyama and Motohiro Okada

Psychopharmacology. Volume 206, Number 2 / October, 2009: 243-258

 

3 - Immunodensity and mRNA expression of A_2A adenosine, D₂ dopamine, and CB₁ cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment

Leyre Urigüen, M. Julia García-Fuster, Luis F. Callado, Benito Morentin, Romano La Harpe, Vicent Casadó, Carmen Lluis, Rafael Franco, Jesús A. García-Sevilla and J. Javier Meana

Psychopharmacology. Volume 206, Number 2 / October, 2009: 313-324

 

GRATIS 3! - Catatonia: A Syndrome Appears, Disappears, and Is Rediscovered

Max Fink

Can J Psychiatry. 2009;54(7):437–445

 

GRATIS 3! - Use of Brain Imaging (Computed Tomography and Magnetic Resonance Imaging) in First-Episode Psychosis: Review and Retrospective Study

Karine Goulet, Benoit Deschamps, François Evoy, Jean-François Trudel

Can J Psychiatry. 2009;54(7):493–501

 

GRATIS 3 - Treatment-Resistant Schizophrenia. Strategies for Recognizing Schizophrenia and Treating to Remission

Seong S. Shim

Psychiatric Times. 2009; Vol. 26 No. 8

 

.

Regresar a RESÚMENES AGOSTO 2009